Skip to main content

Table 1 Clinical characteristics of the patient collective

From: Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer

 

All patients

Occurrence of metastasis

 

n = 84

(100%)

Metachr. Metastasis (n = 37)

Metachr. Metastasis (44%)

p (metachr. Met.)

Sex

Male

54

(64)

25

(46)

0.578

Female

30

(36)

12

(40)

Age (years, median)

 

67 (range 35–86)

37

(44)

0.428

Period of enrollment

before 1993

42

(50)

22

(52)

0.124

1994 and after

42

(50)

15

(36)

Sidedness

Right colon

35

(42)

17

(49)

0.633

Left colon

44

(52)

19

(43)

Unknown

5

(6)

1

(20)

Histology

Adenocarcinoma

75

(89)

34

(46)

0.076

Mucinous adenocarcinoma

7

(9)

1

(14)

Signet ring cell

2

7 (2)

2

(100)

Grading

Low (G1–2)

48

(57)

18

(38)

0.163

High (G3–4)

36

(43)

19

(53)

pT

T1

0

(0)

0

(0)

0.054

T2

6

(7)

4

(67)

T3

57

(68)

20

(35)

T4

21

(25)

13

(62)

pN

N1

58

(69)

19

(33)

0.002a

N2

26

(31)

18

(69)

Lymphatic invasion

L0

57

(68)

25

(44)

0.960

L+

27

(32)

12

(44)

Angioinvasion

V0

79

(94)

34

(43)

0.459

V+

5

(6)

3

(60)

Adjuvant chemotherapy

None

41

(49)

16

(39)

0.500

5-FU alone

27

(32)

12

(44)

other

16

(19)

9

(56)

Alive status

Alive

31

(37)

2

(6)

< 0.001

Tumour rel. Death

33

(39)

33

(100)

Non-tumour rel. Death

20

(24)

2

(10)

Occurrence of met.

No metastases

47

(56)

0

(0)

–

Metachronous metastasis

37

(44)

37

(100)

  1. Note: The p-value refers to differences in the distribution of the factors regarding the risk of metachronous metastasis
  2. afavouring pN1